Cover Image
市場調查報告書

HER2 抗體的全球市場:產業分析·規模·佔有率·成長·趨勢·預測

HER2 Antibodies Market (Type of Treatment Drugs - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, and Everolimus) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 552224
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
HER2 抗體的全球市場:產業分析·規模·佔有率·成長·趨勢·預測 HER2 Antibodies Market (Type of Treatment Drugs - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, and Everolimus) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
出版日期: 2017年08月17日 內容資訊: 英文 112 Pages
簡介

本報告提供全球HER2 抗體市場調查,提供市場概要,對市場成長的各種影響因素及市場機會分析,各治療藥的種類·地區·主要國家趨勢與市場規模的變化與預測,競爭環境,並彙整主要企業的簡介等資訊。

第1章 序文

第2章 前提條件·調查手法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 主要市場指標
  • 市場動態
  • 全球HER2 抗體市場分析·預測
  • 波特的五力分析
  • 市場展望

第5章 全球HER2 抗體市場分析·預測:治療藥的類別

  • 簡介·定義
  • 主要調查結果/發展趨勢
  • 市場規模預測 (以金額為準) :治療藥類別
    • Trastuzumab
    • Lapatinib
    • Ado-trastuzumab emtansine
    • Pertuzumab
    • Everolimus

第6章 全球HER2 抗體市場分析·預測:各地區

  • 主要調查結果
  • 市場規模預測 (以金額為準) :各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力:各國各地區

第7章 北美的HER2 抗體市場分析·預測

  • 簡介
  • 市場規模預測 (以金額為準) :各國
  • 市場魅力:各國
  • 市場規模預測 (以金額為準) :治療藥類別
  • 市場魅力:治療藥類別

第8章 歐洲的HER2 抗體市場分析·預測

第9章 亞太地區的HER2 抗體市場分析·預測

第10章 南美的HER2 抗體市場分析·預測

第11章 中東·非洲 (MEA)的HER2 抗體市場分析·預測

第12章 開發平台分析

第13章 競爭情形

  • 熱圖分析:各企業
  • 企業簡介 (詳細內容 - 概要,財務,近幾年的發展趨勢,策略)
    • Novartis AG
    • Pfizer, Inc.
    • Genentech Inc. (F. Hoffmann-La Roche Ltd.)
    • Abnova Corporation
    • InvivoGen
    • Celltrion, Inc.
    • Biocon Limited
    • Bio-Techne (Novus Biologicals, LLC)

圖表清單

目錄

Global HER2 Antibodies Market: Overview

Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due to over-expression of the HER2 protein. Breast cancers that overexpress the HER2 protein (known as HER2+) make up about 20% of the cases. HER2 positive breast cancer inclines to grow more rapidly than HER2 negative breast cancer. The factors such as being overweight, long term heavy smoking, use of menopausal hormone therapy, alcohol consumption, physical inactivity and many more are responsible for increasing risk of breast cancer. Increasing incidence of breast cancer is expected to lead to increase in demand for targeted therapies and boost the growth of the HER2 antibodies market during the forecast period.

Global HER2 Antibodies Market: Research Methodology

This report analyzes the current and future prospects of the HER2 antibodies market based on type of treatment drugs and geography. The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major HER2 antibody drugs in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each type of treatment drug, and geography for the period 2016 to 2025, considering the macro and micro environmental factors. The revenue generated from each drug was calculated by considering number of drugs used in the treatment and their market demand and sales as per their use, number of new drug launched, trends in industry, awareness, and adoption rate across all the geographies. The prevalence of HER2 breast cancer was also considered while estimating the market revenue.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment drugs and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the HER2 antibodies market in the current and future scenario. The report also provides pipeline analysis of the upcoming drugs for HER2 breast cancer.

Global HER2 Antibodies Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the HER2 antibodies market report are Genentech Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG, Pfizer, Inc., Abnova Corporation, InvivoGen, Celltrion, Inc., Biocon Limited, and Bio-Techne (Novus Biologicals, LLC) and some other players who are involved in the HER2 antibodies market.

The global HER2 Antibodies market is segmented as follows:

Global HER2 Antibodies Market Revenue, by Type of Treatment Drugs

  • Trastuzumab
  • Lapatinib
  • Ado-trastuzumab emtansine
  • Pertuzumab
  • Everolimus
  • ?

Global HER2 Antibodies Market Revenue, by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunities
    • 4.4.4. Trends
  • 4.5. Global HER2 Antibodies Market Analysis and Forecasts, 2015-2025
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Porter's Five Force Analysis
  • 4.7. Market Outlook

5. Global HER2 Antibodies Market, Analysis and Forecasts, By Type of Treatment Drugs

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 5.3.1. Trastuzumab
    • 5.3.2. Lapatinib
    • 5.3.3. Ado-trastuzumab emtansine
    • 5.3.4. Pertuzumab
    • 5.3.5. Everolimus

6. Global HER2 Antibodies Market Analysis and Forecasts, By Region

  • 6.1. Key Findings
  • 6.2. Market Value Forecast by Region
    • 6.2.1. North America
    • 6.2.2. Europe
    • 6.2.3. Asia Pacific
    • 6.2.4. Latin America
    • 6.2.5. Middle East and Africa
  • 6.3. Market Attractiveness by Country/Region

7. North America HER2 Antibodies Market, Analysis and Forecast

  • 7.1. Introduction
    • 7.1.1. Key Findings
    • 7.1.2. Policies and Regulations
    • 7.1.3. Key Trends
  • 7.2. Market Value Forecast by Country, 2015-2025
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Market Attractiveness by Country
  • 7.4. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 7.4.1. Trastuzumab
    • 7.4.2. Lapatinib
    • 7.4.3. Ado-trastuzumab emtansine
    • 7.4.4. Pertuzumab
    • 7.4.5. Everolimus
  • 7.5. Market Attractiveness by Type of Treatment Drugs

8. Europe HER2 Antibodies Market, Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Key Findings
    • 8.1.2. Policies and Regulations
    • 8.1.3. Key Trends
  • 8.2. Market Value Forecast by Country, 2015-2025
    • 8.2.1. U.K.
    • 8.2.2. Germany
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Rest of Europe
  • 8.3. Market Attractiveness by Country
  • 8.4. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 8.4.1. Trastuzumab
    • 8.4.2. Lapatinib
    • 8.4.3. Ado-trastuzumab emtansine
    • 8.4.4. Pertuzumab
    • 8.4.5. Everolimus
  • 8.5. Market Attractiveness by Type of Treatment Drugs

9. Asia Pacific HER2 Antibodies Market, Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
    • 9.1.2. Policies and Regulations
    • 9.1.3. Key Trends
  • 9.2. Market Value Forecast by Country, 2015-2025
    • 9.2.1. Japan
    • 9.2.2. China
    • 9.2.3. India
    • 9.2.4. Australia & New Zealand
    • 9.2.5. Rest of Asia Pacific
  • 9.3. Market Attractiveness by Country
  • 9.4. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 9.4.1. Trastuzumab
    • 9.4.2. Lapatinib
    • 9.4.3. Ado-trastuzumab emtansine
    • 9.4.4. Pertuzumab
    • 9.4.5. Everolimus
  • 9.5. Market Attractiveness by Type of Treatment Drugs

10. Latin America HER2 Antibodies Market, Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
    • 10.1.3. Key Trends
  • 10.2. Market Value Forecast by Country, 2015-2025
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of LATAM
  • 10.3. Market Attractiveness by Country
  • 10.4. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 10.4.1. Trastuzumab
    • 10.4.2. Lapatinib
    • 10.4.3. Ado-trastuzumab emtansine
    • 10.4.4. Pertuzumab
    • 10.4.5. Everolimus
  • 10.5. Market Attractiveness by Type of Treatment Drugs

11. Middle East & Africa HER2 Antibodies Market, Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Policies and Regulations
    • 11.1.3. Key Trends
  • 11.2. Market Value Forecast by Country, 2015-2025
    • 11.2.1. Saudi Arabia
    • 11.2.2. South Africa
    • 11.2.3. Rest of MEA
  • 11.3. Market Attractiveness by Country
  • 11.4. Market Value Forecast by Type of Treatment Drugs, 2015-2025
    • 11.4.1. Trastuzumab
    • 11.4.2. Lapatinib
    • 11.4.3. Ado-trastuzumab emtansine
    • 11.4.4. Pertuzumab
    • 11.4.5. Everolimus
  • 11.5. Market Attractiveness by Type of Treatment Drugs

12. Pipeline Analysis

  • 12.1. Pipeline Snapshot for HER2 Antibodies Market

13. Competition Landscape

  • 13.1. Heat Map Analysis by Company (2016)
  • 13.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 13.2.1. Novartis AG
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.2. Pfizer, Inc.
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.3. Genentech Inc. (F. Hoffmann-La Roche Ltd.)
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.4. Abnova Corporation
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.5. InvivoGen
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.6. Celltrion, Inc.
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.7. Biocon Limited
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview
    • 13.2.8. Bio-Techne (Novus Biologicals, LLC)
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Overview
      • 13.2.1.3. Financial Overview
      • 13.2.1.4. SWOT Analysis
      • 13.2.1.5. Strategic Overview

List of Tables

  • Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025
  • Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025
  • Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025
  • Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025
  • Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025
  • Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015-2025

List of Figures

  • Figure 01: HER2 Antibodies Market, by Type of Treatment Drugs, Market Size (US$ Mn), 2016 (A)
  • Figure 02: HER2 antibodies market revenue (%), by top three drugs, 2016 (A)
  • Figure 03: Executive Summary (2/3)
  • Figure 04: Executive Summary (3/3)
  • Figure 05: Opportunity Map, 2017
  • Figure 06: Key Industry Developments
  • Figure 07: Drivers and Restraints Snapshot (1/1)
  • Figure 08: Global HER2 Antibodies Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 09: Porter's Five Forces Analysis (1/2)
  • Figure 10: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs (2016)
  • Figure 11: Global HER2 Antibodies Market Value Share, by Region (2016)
  • Figure 12: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 13: Global HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 14: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Trastuzumab, 2015-2025
  • Figure 15: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lapatinib, 2015-2025
  • Figure 16: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Ado-trastuzumab Emtansine, 2015-2025
  • Figure 17: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pertuzumab, 2015-2025
  • Figure 18: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Everolimus, 2015-2025
  • Figure 19: Global Market Scenario
  • Figure 20: Global HER2 Antibodies Market Value Share, by Region, 2017 and 2025
  • Figure 21: Global HER2 Antibodies Market Attractiveness, by Region, 2017-2025
  • Figure 22: North America HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015-2025
  • Figure 23: North America HER2 Antibodies Market Attractiveness Analysis, by Country
  • Figure 24: North America HER2 Antibodies Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 25: North America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 26: North America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 27: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015-2025
  • Figure 28: Europe HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 29: Europe Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 30: Europe HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 31: Europe HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 32: Asia Pacific HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Figure 33: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country. 2017-2025
  • Figure 34: Asia Pacific Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 35: Asia Pacific HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 36: Asia Pacific HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 37: Latin America HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Figure 38: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 39: Latin America Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 40: Latin America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 41: Latin America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 42: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) and
  • Figure 43: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
  • Figure 44: Middle East & Africa Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 45: Middle East & Africa HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
  • Figure 46: Middle East & Africa HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017-2025
  • Figure 47: Pipeline Snapshot of HER2 Antibodies Market (1/2)
  • Figure 48: Pipeline Snapshot of HER2 Antibodies Market (2/2)
  • Figure 49: Global HER2 Antibodies Market Heat Map Analysis by Company (2016)
  • Figure 50: Novartis AG Breakdown of Net Sales, by Region (2016)
  • Figure 51: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 52: Pfizer, Inc. Breakdown of Net Sales, by Region (2016)
  • Figure 53: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 54: Genentech Inc. Breakdown of Net Sales, by Segment, 2016
  • Figure 55: Genentech Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 56: Abnova Corporation Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 57: Celltrion, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2015
  • Figure 58: Biocon Limited Breakdown of Net Sales, by Business Segments, 2016
  • Figure 59: Biocon Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 60: Bio-Techne Breakdown of Net Sales, by Business Segment, 2016
  • Figure 61: Bio-Techne Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
Back to Top